Hakeem, I.J.; Alahdal, H.; Baeissa, H.M.; Bakhsh, T.; Rafeeq, M.; Habib, A.H.; Karami, M.M.; AL-Ghamdi, M.A.; Abdullah, G.; Al Tuwaijri, A.
Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease. Pharmaceuticals 2025, 18, 772.
https://doi.org/10.3390/ph18060772
AMA Style
Hakeem IJ, Alahdal H, Baeissa HM, Bakhsh T, Rafeeq M, Habib AH, Karami MM, AL-Ghamdi MA, Abdullah G, Al Tuwaijri A.
Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease. Pharmaceuticals. 2025; 18(6):772.
https://doi.org/10.3390/ph18060772
Chicago/Turabian Style
Hakeem, Israa J., Hadil Alahdal, Hanadi M. Baeissa, Tahani Bakhsh, Misbahuddin Rafeeq, Alaa Hamed Habib, Mohammed Matoog Karami, Maryam A. AL-Ghamdi, Ghadeer Abdullah, and Abeer Al Tuwaijri.
2025. "Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease" Pharmaceuticals 18, no. 6: 772.
https://doi.org/10.3390/ph18060772
APA Style
Hakeem, I. J., Alahdal, H., Baeissa, H. M., Bakhsh, T., Rafeeq, M., Habib, A. H., Karami, M. M., AL-Ghamdi, M. A., Abdullah, G., & Al Tuwaijri, A.
(2025). Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer’s Disease. Pharmaceuticals, 18(6), 772.
https://doi.org/10.3390/ph18060772
